<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301652</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0607</org_study_id>
    <nct_id>NCT00301652</nct_id>
  </id_info>
  <brief_title>MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis</brief_title>
  <official_title>Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Treatment of ANCA Associated Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to access the efficacy of MMF compared to CTX in inducing&#xD;
      remission and improving renal function in subjects with ANCA associated vasculitis with renal&#xD;
      involvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ANCA-associated vasculitides can be life threatening. Glucocorticoids and&#xD;
      cyclophosphamide therapy is effective in about 80% patients. However, the side effects such&#xD;
      as bone marrow suppression, infection, cystitis, infertility, myelodysplasia preclude further&#xD;
      use of cyclophosphamide in some patients and the relapse rate is high.&#xD;
&#xD;
      Recent studies have shown that mycophenolic acid(MPA), the active metabolite of mycophenolate&#xD;
      mofetil(MMF), could exhibit multifarious effects on endothelial cells, including inhibition&#xD;
      of ICAM-1 expression, neutrophil attachment,IL-6 secretion, and the process of angiogenesis,&#xD;
      which contribute to the efficacy of MMF in the treatment of vasculitic lesions such as lupus&#xD;
      nephritis with vasculitic lesions. This study was a feasibility study to assess the safety&#xD;
      and effectiveness of MMF in inducing remission in subjects with ANCA-associated SVV compared&#xD;
      with pulse intravenous cyclophosphamide. After enrollment, subjects were followed&#xD;
      longitudinally, and formal measurements of disease activity were determined using the&#xD;
      Birmingham Vasculitis Activity Score (BVAS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of MMF compared to CTX in inducing remission and improving renal function in subjects with ANCA associated vasculitis.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Vasculitis</condition>
  <condition>Anti-Neutrophil Cytoplasmic Antibody</condition>
  <arm_group>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>MMF,1.0g/d</description>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <other_name>MMF,cellcept,mycophenolate mofetil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A new diagnosis of ANCA associated vasculitis (eg. MPA or Wegener granulomatous, or&#xD;
             renal limited vasculitis) proved by histology and serology.&#xD;
&#xD;
          2. Renal involvement attributable to active ANCA associated vasculitis with at least one&#xD;
             of the following:&#xD;
&#xD;
               -  Elevated serum creatinine between 150 and 500 umol/l - renal biopsy&#xD;
&#xD;
               -  Demonstrating paucin -immune necrotizing glomerulonephritis&#xD;
&#xD;
               -  Red cell casts&#xD;
&#xD;
               -  Haematuria with &gt; 30 red blood cells/HPF and proteinuria &gt; 1g/24h&#xD;
&#xD;
          3. Serum ANCA positive by indirect immunofluorescence (IIF) and positivity in the&#xD;
             anti-PR3 or anti-MPO by ELISA&#xD;
&#xD;
          4. Age 18~65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than two weeks treatment with cyclophosphamide (CYC) or other cytotoxic drug&#xD;
             within previous 6 months or with oral corticosteroids (OCS) for more than 4 weeks&#xD;
&#xD;
          2. Co-existence of another multisystem autoimmune disease, e.g. SLE&#xD;
&#xD;
          3. Serum creatinine &gt; 500umol/l&#xD;
&#xD;
          4. Severe viral infection(HBV, HCV, CMV) within 3 months of first randomization or known&#xD;
             HIV infection&#xD;
&#xD;
          5. Congenial or acquired immunodeficiency&#xD;
&#xD;
          6. Immediately life-threatening organ manifestations (e.g. lung haemorrhage or dialysis&#xD;
             dependence)&#xD;
&#xD;
          7. Previous malignancy&#xD;
&#xD;
          8. Pregnancy or inadequate contraception if female&#xD;
&#xD;
          9. Anti-GBM antibody positivity&#xD;
&#xD;
         10. Cerebral infarction due to vasculitis&#xD;
&#xD;
         11. Rapidly progressive optic neuropathy or retinal vasculitis or orbital pseudotumour&#xD;
&#xD;
         12. Massive gastro-intestinal bleeding&#xD;
&#xD;
         13. Heart failure due to pericarditis or myocarditis&#xD;
&#xD;
         14. Liver dysfunction measured on at least 2 separate occasions&#xD;
&#xD;
         15. Age &lt; 18y or Age &gt; 65y&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei-Shi Li, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 10, 2006</study_first_submitted>
  <study_first_submitted_qc>March 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <last_update_submitted>June 7, 2010</last_update_submitted>
  <last_update_submitted_qc>June 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name_title>
    <organization>Nanjing University School of Medicine</organization>
  </responsible_party>
  <keyword>ANCA</keyword>
  <keyword>vasculitis</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

